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not suitable for therapeutic drug monitoring of patients
with cystic fibrosis
We read with interest the paper by Madsen et al. [1] who
reported that tobramycin could not be detected in saliva
within the first 6 h after once daily dosing, concluding that
plasma cannot be substituted with saliva for the therapeutic
drug monitoring(TDM) of patients with cystic fibrosis(CF).
Madsen et al. mention in their paper two short reports
describing the use of saliva as an alternative to serum for
monitoring once daily gentamicin in children [2,3]. These
studies confirmed a correlation between salivary and serum
levels; however, none of these subjects had toxic levels, and
therefore, this system has not been tested for its ability to
detect such levels. Berkovitch et al. proposed that it takes
longer for gentamicin to enter and equilibrate with the
saliva, hence the correlation between serum and saliva
levels only when gentamicin was given once daily as
opposed to a twice daily or thrice daily regime in their study
[2,3].
We wish to describe our own experience of using saliva
as an alternative to plasma for TDM of children with CF. We
studied 24 children who were prescribed once daily
gentamicin (n =19) or tobramycin (n =5) at a dosage of
10–12 mg/kg/day for a chest exacerbation. Median (range)
age was 10 years (6.9 to 16.75).
Trough serum and saliva samples were obtained 48 h
after drug initiation, prior to administration of the 3rd dose.
Citric acid crystals were used to stimulate saliva flow if
necessary. In addition, in an attempt to assess the ability of
the test to detect dtoxicT levels, 4 patients (tobramycin (n =3)
and gentamicin (n =1)) also had paired plasma and saliva
samples taken at various post-dose time points (1, 3, 5 and 7
h) when serum levels were predicted to be high. Levels were
estimated using the Abbott TDx system (Abbott laboratories
Ltd., Maidenhead, UK), which uses fluorescence polar-
ization immunoassay (FPIA) technology. The lower limits
of detection (distinguished from zero with 95% confidence)
in our laboratory were 0.27 mg/L for gentamicin and 0.18
mg/L for tobramycin.
Our results showed that pre-dose correlation was poor
(R =0.213 and p =0.213). Post-dose (up to 7 h) all serum1569-1993/$ - see front matter D 2005 Published by Elsevier B.V. on behalf of E
doi:10.1016/j.jcf.2005.05.016levels were high, range (2.1–22.0); despite this, none of the
saliva samples were N1 (0.07–0.94), i.e., toxicity was not
detected in a single case.
Although aminoglycosides could be detected in saliva,
there was no correlation between absolute levels of saliva
and serum of either tobramycin or gentamicin levels in
patients with CF at any time point measured. Most
importantly, in every case, a high serum level would have
been missed on salivary testing. Plasma cannot be sub-
stituted by saliva for TDM of tobramycin or gentamicin in
patients with CF.References
[1] Madsen V, Lind A, Rasmussen M, Coulthard K. Determination of
tobramycin in saliva is not suitable for therapeutic drug monitoring of
patients with cystic fibrosis. J Cyst Fibros 2004;3:249–51.
[2] Berkovitch M, Bistritzer T, Aladjem M, Burtin P, Dagan T, Chen-Levi
Z, et al. Clinical relevance of therapeutic drug monitoring of digoxin
and gentamicin in the saliva of children. Ther Drug Monit
1998;20:253–6.
[3] Berkovitch M, Goldman M, Silverman R, Chen-Levi Z, Greenberg R,
Marcus O, et al. Therapeutic drug monitoring of once daily gentamicin
in serum and saliva of children. Eur J Pediatr 2000;159:697–8.Helen Spencer4
Wanda Kozlowska
Jane C. Davies
Paediatric Respiratory Department,
The Royal Brompton Hospital, London,
SW36NP, United Kingdom
E-mail address: spench@gosh.nhs.uk.
4Corresponding author.
Peter Webber
Maureen Chadwick
Jonathan Kerr
Microbiology Department, The Royal Brompton Hospital,
London, SW3 6NP, United Kingdom
Sukeshi Makhecha
Pharmacy Department, The Royal Brompton Hospital,
London, SW3 6NP, United Kingdomsis 4 (2005) 209uropean Cystic Fibrosis Society.
